Fluorescent-guided surgery for liver cancer using GPC3 dye
Part of Cancer, Digestive system clinical trials.
This trial studies whether a special fluorescent dye that targets GPC3 can help surgeons find liver cancer more clearly during an operation. It may improve how accurately tumor tissue is identified while you have surgery for hepatocellular carcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer).
- Your doctors are planning a liver surgery called hepatectomy (removing part of the liver).
- Your liver function is good enough for surgery, in the Child-Pugh A or B category.
- Before surgery, tests show your tumor has high GPC3 (a marker the dye is meant to stick to).
- You are between 18 and 75 years old and expected to live more than 6 months (based on your doctor’s estimate).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special dye that lights up during surgery to help doctors see and remove liver cancer cells that have a specific protein (ITGA6). It aims to make surgery more precise and effective.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
This trial tests a new type of cell therapy called C-CAR031, which is designed to target and attack liver cancer cells that have a protein called GPC3. It is for people with advanced liver cancer who have already tried other treatments and are looking for a new option.
This trial tests CAR-T cell therapy (immune cells changed to target GPC-3) for advanced hepatocellular carcinoma, especially when standard treatments no longer work or you cannot tolerate them. If eligible, the goal is to shrink tumors and help you live longer with improved cancer control.
This trial tests a new way to remove liver cancer during surgery. A special dye called ICG is injected into the artery leading to the liver, which makes the tumor glow under a special camera, helping the surgeon remove just the right area. This study checks if this technique is both safe and effective for people with a common type of liver cancer (hepatocellular carcinoma).
This trial tests a new way to help surgeons see liver tumors more clearly during keyhole (laparoscopic) surgery. A special dye (ICG) is used with a camera to guide the surgeon in removing just the right part of the liver. It may lead to safer and more precise surgery for people with liver cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.